Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any cone-rod dystrophy in which the cause of the disease is a mutation in the CDHR1 gene.
Features include always present findings: Progressive visual loss; and sometimes findings: Nyctalopia and Photophobia. 8 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 3 | Color vision defect, Retinal pigment epithelial atrophy, Attenuation of retinal blood vessels |
CDHR1 encodes cadherin related family member 1 (859 aa). Potential calcium-dependent cell-adhesion protein. May be required for the structural integrity of the outer segment (OS) of photoreceptor cells Highest expression in Skin Not Sun Exposed Suprapubic (234.9 TPM) and Skin Sun Exposed Lower leg (225.7 TPM).
Cone-rod dystrophy 15 is associated with mutations in the CDHR1 gene on chromosome 10.
CDHR1 is classified as a druggable target with score 0.0.
Genetic testing for CDHR1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for cone-rod dystrophy 15 has been reported in the published literature.
Phenotype severity distribution: 1 always present feature.
No clinical trials have been registered for cone-rod dystrophy 15.
44 publications have been identified in PubMed for cone-rod dystrophy 15. Research spans Basic Science / Preclinical (27%), Epidemiology / Natural History (27%), and Case Report / Case Series (20%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 12 | 27% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:53 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about cone-rod dystrophy 15
1 |
Retinal pigment epithelial atrophy |
12 |
27% |
Patient case studies | 9 | 20% |
Research summaries | 5 | 11% |
New treatment approaches | 3 | 7% |
Testing and diagnosis research | 2 | 5% |
Other research | 1 | 2% |
Clérin E (2026). [PMID: 41769936](https://pubmed.ncbi.nlm.nih.gov/41769936/). *Invest Ophthalmol Vis Sci*. [Gene Therapy / Novel Therapeutics]
Hirakata T (2026). [PMID: 41728201](https://pubmed.ncbi.nlm.nih.gov/41728201/). *Front Ophthalmol (Lausanne)*. [Basic Science / Preclinical]
Patel MK (2026). [PMID: 41995082](https://pubmed.ncbi.nlm.nih.gov/41995082/). *Elife*. [Basic Science / Preclinical]
Fabard M (2026). [PMID: 41686256](https://pubmed.ncbi.nlm.nih.gov/41686256/). *Hum Genet*. [Basic Science / Preclinical]
Patel MK (2026). [PMID: 41648145](https://pubmed.ncbi.nlm.nih.gov/41648145/). *bioRxiv*. [Basic Science / Preclinical]
Li M (2026). [PMID: 41827476](https://pubmed.ncbi.nlm.nih.gov/41827476/). *J Clin Med*. [Case Report / Case Series]
de Guimarães TAC (2026). [PMID: 42071308](https://pubmed.ncbi.nlm.nih.gov/42071308/). *Ophthalmic Genet*. [Diagnostic / Biomarker]
Mahler EA (2026). [PMID: 41238926](https://pubmed.ncbi.nlm.nih.gov/41238926/). *Ophthalmologie*. [Other]
Varughese RS (2026). [PMID: 42044156](https://pubmed.ncbi.nlm.nih.gov/42044156/). *J Clin Endocrinol Metab*. [Epidemiology / Natural History]
Takács Á (2026). [PMID: 41595520](https://pubmed.ncbi.nlm.nih.gov/41595520/). *Genes (Basel)*. [Epidemiology / Natural History]